Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years

Carlo Selmi, Angela Ceribelli, Elena Generali, Carlo A. Scirè, Fausto Alborghetti, Guido Colloredo, Luisa Porrati, Maria I S Achenza, Maria De Santis, Francesca Cavaciocchi, Marco Massarotti, Natasa Isailovic, Valentina Paleari, Pietro Invernizzi, Torsten Matthias, Alberto Zucchi, Pier Luigi Meroni

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The prevalence of ANA and anti-ENA in the general population is not well established, especially their clinical significance in healthy subjects. We herein determined the prevalence and predictive value of serum ANA and anti-ENA for connective tissue diseases (CTD), cancer, and mortality. We took advantage of a randomly selected sample of the 1998 general population (Isola I) consisting of 2828 subjects (53% women, age 43 ± 13 years) from a well-defined Northern Italian area. Serum ANA and anti-ENA were tested on the 2690 samples available in 2012 (Isola II, 50% women, age 58 ± 13 years). Administrative databases were searched for CTD, cancer diagnosis, and death cases occurring between enrollment and December 31, 2013. The hazard ratio (HR) was calculated for incident cases. Serum ANA is positive in 18.1% for any titer and 6.1% for titers ≥ 1:160, 23% in subjects over 50 years and 13.1% and 6.1% for any titer and titers ≥ 1:160, respectively, in women. The HR for CTD development was significantly high for all ANA titers, with the highest for ANA ≥ 1:160 (HR 14.19, 95% CI 3.07-65.68). ANA positivity was not associated with cancer (HR 1.03; 95% CI 0.75-1.43), or with mortality (HR adjusted for age and sex 1.40; 95% CI 0.94-2.09). Serum anti-ENA is positive in a minority of subjects with highest figures for anti-nucleosome (1.9%), -histone (1.6%) and -PM/Scl (1.5%). In conclusion, serum ANA prevalence in the general population is highest in senior subjects and in women, while the female predominance is significantly lower compared to overt CTD. Serum ANA is associated with an increased probability of CTD development over time, but does not influence survival or cancer risk.

Original languageEnglish (US)
Pages (from-to)162-166
Number of pages5
JournalAutoimmunity Reviews
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Nuclear Antigens
Connective Tissue Diseases
Morbidity
Mortality
Antibodies
Serum
Population
Neoplasms
Nucleosomes
Histones
Healthy Volunteers
Databases
Survival

Keywords

  • Age
  • Autoimmunity
  • Cancer
  • Clinical epidemiology
  • Connective tissue disease
  • Gender
  • Survival

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years. / Selmi, Carlo; Ceribelli, Angela; Generali, Elena; Scirè, Carlo A.; Alborghetti, Fausto; Colloredo, Guido; Porrati, Luisa; Achenza, Maria I S; De Santis, Maria; Cavaciocchi, Francesca; Massarotti, Marco; Isailovic, Natasa; Paleari, Valentina; Invernizzi, Pietro; Matthias, Torsten; Zucchi, Alberto; Meroni, Pier Luigi.

In: Autoimmunity Reviews, Vol. 15, No. 2, 01.02.2016, p. 162-166.

Research output: Contribution to journalArticle

Selmi, C, Ceribelli, A, Generali, E, Scirè, CA, Alborghetti, F, Colloredo, G, Porrati, L, Achenza, MIS, De Santis, M, Cavaciocchi, F, Massarotti, M, Isailovic, N, Paleari, V, Invernizzi, P, Matthias, T, Zucchi, A & Meroni, PL 2016, 'Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years', Autoimmunity Reviews, vol. 15, no. 2, pp. 162-166. https://doi.org/10.1016/j.autrev.2015.10.007
Selmi, Carlo ; Ceribelli, Angela ; Generali, Elena ; Scirè, Carlo A. ; Alborghetti, Fausto ; Colloredo, Guido ; Porrati, Luisa ; Achenza, Maria I S ; De Santis, Maria ; Cavaciocchi, Francesca ; Massarotti, Marco ; Isailovic, Natasa ; Paleari, Valentina ; Invernizzi, Pietro ; Matthias, Torsten ; Zucchi, Alberto ; Meroni, Pier Luigi. / Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years. In: Autoimmunity Reviews. 2016 ; Vol. 15, No. 2. pp. 162-166.
@article{018801e743b34e2eb3ca769f6a43a531,
title = "Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years",
abstract = "The prevalence of ANA and anti-ENA in the general population is not well established, especially their clinical significance in healthy subjects. We herein determined the prevalence and predictive value of serum ANA and anti-ENA for connective tissue diseases (CTD), cancer, and mortality. We took advantage of a randomly selected sample of the 1998 general population (Isola I) consisting of 2828 subjects (53{\%} women, age 43 ± 13 years) from a well-defined Northern Italian area. Serum ANA and anti-ENA were tested on the 2690 samples available in 2012 (Isola II, 50{\%} women, age 58 ± 13 years). Administrative databases were searched for CTD, cancer diagnosis, and death cases occurring between enrollment and December 31, 2013. The hazard ratio (HR) was calculated for incident cases. Serum ANA is positive in 18.1{\%} for any titer and 6.1{\%} for titers ≥ 1:160, 23{\%} in subjects over 50 years and 13.1{\%} and 6.1{\%} for any titer and titers ≥ 1:160, respectively, in women. The HR for CTD development was significantly high for all ANA titers, with the highest for ANA ≥ 1:160 (HR 14.19, 95{\%} CI 3.07-65.68). ANA positivity was not associated with cancer (HR 1.03; 95{\%} CI 0.75-1.43), or with mortality (HR adjusted for age and sex 1.40; 95{\%} CI 0.94-2.09). Serum anti-ENA is positive in a minority of subjects with highest figures for anti-nucleosome (1.9{\%}), -histone (1.6{\%}) and -PM/Scl (1.5{\%}). In conclusion, serum ANA prevalence in the general population is highest in senior subjects and in women, while the female predominance is significantly lower compared to overt CTD. Serum ANA is associated with an increased probability of CTD development over time, but does not influence survival or cancer risk.",
keywords = "Age, Autoimmunity, Cancer, Clinical epidemiology, Connective tissue disease, Gender, Survival",
author = "Carlo Selmi and Angela Ceribelli and Elena Generali and Scir{\`e}, {Carlo A.} and Fausto Alborghetti and Guido Colloredo and Luisa Porrati and Achenza, {Maria I S} and {De Santis}, Maria and Francesca Cavaciocchi and Marco Massarotti and Natasa Isailovic and Valentina Paleari and Pietro Invernizzi and Torsten Matthias and Alberto Zucchi and Meroni, {Pier Luigi}",
year = "2016",
month = "2",
day = "1",
doi = "10.1016/j.autrev.2015.10.007",
language = "English (US)",
volume = "15",
pages = "162--166",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Serum antinuclear and extractable nuclear antigen antibody prevalence and associated morbidity and mortality in the general population over 15years

AU - Selmi, Carlo

AU - Ceribelli, Angela

AU - Generali, Elena

AU - Scirè, Carlo A.

AU - Alborghetti, Fausto

AU - Colloredo, Guido

AU - Porrati, Luisa

AU - Achenza, Maria I S

AU - De Santis, Maria

AU - Cavaciocchi, Francesca

AU - Massarotti, Marco

AU - Isailovic, Natasa

AU - Paleari, Valentina

AU - Invernizzi, Pietro

AU - Matthias, Torsten

AU - Zucchi, Alberto

AU - Meroni, Pier Luigi

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The prevalence of ANA and anti-ENA in the general population is not well established, especially their clinical significance in healthy subjects. We herein determined the prevalence and predictive value of serum ANA and anti-ENA for connective tissue diseases (CTD), cancer, and mortality. We took advantage of a randomly selected sample of the 1998 general population (Isola I) consisting of 2828 subjects (53% women, age 43 ± 13 years) from a well-defined Northern Italian area. Serum ANA and anti-ENA were tested on the 2690 samples available in 2012 (Isola II, 50% women, age 58 ± 13 years). Administrative databases were searched for CTD, cancer diagnosis, and death cases occurring between enrollment and December 31, 2013. The hazard ratio (HR) was calculated for incident cases. Serum ANA is positive in 18.1% for any titer and 6.1% for titers ≥ 1:160, 23% in subjects over 50 years and 13.1% and 6.1% for any titer and titers ≥ 1:160, respectively, in women. The HR for CTD development was significantly high for all ANA titers, with the highest for ANA ≥ 1:160 (HR 14.19, 95% CI 3.07-65.68). ANA positivity was not associated with cancer (HR 1.03; 95% CI 0.75-1.43), or with mortality (HR adjusted for age and sex 1.40; 95% CI 0.94-2.09). Serum anti-ENA is positive in a minority of subjects with highest figures for anti-nucleosome (1.9%), -histone (1.6%) and -PM/Scl (1.5%). In conclusion, serum ANA prevalence in the general population is highest in senior subjects and in women, while the female predominance is significantly lower compared to overt CTD. Serum ANA is associated with an increased probability of CTD development over time, but does not influence survival or cancer risk.

AB - The prevalence of ANA and anti-ENA in the general population is not well established, especially their clinical significance in healthy subjects. We herein determined the prevalence and predictive value of serum ANA and anti-ENA for connective tissue diseases (CTD), cancer, and mortality. We took advantage of a randomly selected sample of the 1998 general population (Isola I) consisting of 2828 subjects (53% women, age 43 ± 13 years) from a well-defined Northern Italian area. Serum ANA and anti-ENA were tested on the 2690 samples available in 2012 (Isola II, 50% women, age 58 ± 13 years). Administrative databases were searched for CTD, cancer diagnosis, and death cases occurring between enrollment and December 31, 2013. The hazard ratio (HR) was calculated for incident cases. Serum ANA is positive in 18.1% for any titer and 6.1% for titers ≥ 1:160, 23% in subjects over 50 years and 13.1% and 6.1% for any titer and titers ≥ 1:160, respectively, in women. The HR for CTD development was significantly high for all ANA titers, with the highest for ANA ≥ 1:160 (HR 14.19, 95% CI 3.07-65.68). ANA positivity was not associated with cancer (HR 1.03; 95% CI 0.75-1.43), or with mortality (HR adjusted for age and sex 1.40; 95% CI 0.94-2.09). Serum anti-ENA is positive in a minority of subjects with highest figures for anti-nucleosome (1.9%), -histone (1.6%) and -PM/Scl (1.5%). In conclusion, serum ANA prevalence in the general population is highest in senior subjects and in women, while the female predominance is significantly lower compared to overt CTD. Serum ANA is associated with an increased probability of CTD development over time, but does not influence survival or cancer risk.

KW - Age

KW - Autoimmunity

KW - Cancer

KW - Clinical epidemiology

KW - Connective tissue disease

KW - Gender

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84954400055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954400055&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2015.10.007

DO - 10.1016/j.autrev.2015.10.007

M3 - Article

VL - 15

SP - 162

EP - 166

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 2

ER -